JCAR 017

Drug Profile

JCAR 017

Alternative Names: 4-1BB-modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR017

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Seattle Children's Hospital
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Sep 2017 Juno Therapeutics anticipates US FDA approval for JCAR 017 for Non-Hodgkin's lymphoma by 2018
  • 30 Jun 2017 JCAR 017 receives Orphan Drug status for Diffuse large B cell lymphoma in European Union
  • 17 Jun 2017 Juno Therapeutics plans a pivotal trial in patients with Diffuse large B cell lymphoma in the US in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top